Tyra Biosciences (TYRA)

• Market cap: $1.64B
• 1 day: -4.7%
• 5 days: 2.36%
• 1 month: 21.15%
• 3 months: 96.56%
• 6 months: 176.41%
• Year to date: 15.04%
• 1 year: 109.52%
• 5 years: 18.54%
• 10 years: 18.54%
• Sector: Healthcare
• Industry: Biotechnology

About: Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Employees: 60